Targeted in vitro- confirmation of the antiviral activity of Tenvir (Tenofovir) drug against the SARS-COV-2 virus variant B. in Kazakhstan and identifying NSP12 in the viral genome
Main Article Content
Authors
S. Khaidarov
KazNU named after Al Farabi, Al Farabi Ave. 71, Almaty, Kazakhstan
Y. Burashev
Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan
N. Kozhabergenov
Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan
B. Usserbayev
Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan
A. Melisbek
Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan
M. Shirinbekov
Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan
A. Moldakaryzova
Department of molecular biology and medical genetics at the Kazakh National Medical University, Almaty, Kazakhstan
A. Beisenova
Department of molecular biology and medical genetics at the Kazakh National Medical University, Almaty, Kazakhstan
A. Mustafaeva
Department of molecular biology and medical genetics at the Kazakh National Medical University, Almaty, Kazakhstan
A. Kydyrbaeva
Department of molecular biology and medical genetics at the Kazakh National Medical University, Almaty, Kazakhstan
Abstract
COVID-19 became a true medication target worldwide due to its pandemic scale in 2020. Viral infections are generally hard to cope with, especially, if the viral load and spreading speed seriously surpass the immune reaction, both innate and adaptive. Thus, only relatively few drugs were used clinically to stop either in the early stages of viral reproduction like with the help of Tenvir (Tenofovir) or vaccination to gain collective immunity in a particular population. None of the interferon-based drugs showed clear medical effects in medical trials and during pandemic hospitalization protocols. However, purine-analogs like Tenvir and others showed sustainable survival and recovery rates among SARS-COV-2 virus-infected patients at moderate and severe stages of pneumonia caused by this virus. This article reveals the invitro testing of the Tenvir drug on virus strain, Variant B.1.1, Sampled from Kazakhstan and molecular-genetic characterization of NSP12 (non-structural protein 12) located in ORF1b region of the SARS-COV 2 genome. Tenvir or tenofovir was broadly used against HIV infection and this study shows a sufficient effect on viral spread due to RdRP-inhibiting properties in-vitro.
Keywords
COVID-19, NSP-12, RNA dependent RNA-Polymerase (RdRP), purine-analogs, RT-PCR, Gene-product
Article Details
References
Platto, S., Xue, T. & Carafoli, E. COVID19: an announced pandemic. Cell Death Dis-2020Vol. N799.-P. 11.Crossref
Burashev Y., et al. Coding Complete Genome Sequence of the SARS-CoV-2 Virus Strain, Variant B.1.1, Sampled from Kazakhstan - 2022, Microbiology Resource Announcements. Crossref.
Usserbayev Bekbolat et. al., Near-Complete Genome Sequence of a SARS-CoV-2 Variant B.1.1.7 Virus Strain Isolated in Kazakhstan - 2022. Journals Microbiology Resource Announcements. Crossref
Deng, X.; Baker, S.C. "Coronaviruses: Molecular Biology (Coronaviridae)", Encyclopedia of Virology -2021.-Vol.12, N8. P. 198–207. doi:10.1016/B978-0-12-814515-9.02550-9. ISBN 9780128145166
Hui Hui Wong, To Sing Fung, Shouguo Fang, Mei Huang, My Tra Le, Ding Xiang Liu, Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor3 -2018. Virology, Vol. 515,N136.- P. 165-175, Crossref.
Alanagreh, L., Alzoughool, F., Atoum, M. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. -2020. Pathogens, Vol. 9, N127. P. 331. Crossref
Lu R., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding -2020. Lancet Vol. 395. - P565–574, Crossref.
Zhang Y.Z., Holmes EC. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.-2020 Cell. Vol.181, N2. P. 223-227. doi: 10.1016/j.cell.2020.03.035. Epub 2020 Mar 26. PMID: 32220310; PMCID: PMC7194821.
Roe M.K. et al., Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19 -2021. Journal of General Virology -Vol.102, N2.-P123-127: Crossref.
Delang L., Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. -2018. Antiviral Res. Vol. 153, -P. 85-94. doi: 10.1016/j.antiviral.2018.03.003. Epub 2018 Mar 7. PMID: 29524445.
Wang M., Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. – 2020. Cell Res. Vol30 N3.-P. 269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. PMID: 32020029; PMCID: PMC7054408.
Lee M. J., Kim KH, Yi J, Choi SJ, Choe PG, Park WB, Kim NJ, Oh MD. In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus-2017. Korean J Intern Med. Vol.4.-P.731-737. doi: 10.3904/kjim.2016.109. Epub 2016 Nov 30. PMID: 27899013; PMCID: PMC5511939.
Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis-2015. Methods Mol. Biol. Vol.1282.-P. 1–23.
Muhammad Hamdan Gul, Zin Mar Htun, Nauman Shaukat, Muhammad Imran and Ahmad Khan. Potential specific therapies in COVID-19.- 2020. Ther Adv Respir Dis.- Vol. 14.-P. 1–12 DOI: 10.1177/1753466620926853, URL
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M.,Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y.,Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D., Wang, C., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.-2020. New Engl. J. Med. Vol. 382.-P.1787–1799. Crossref N E J Moa 2001282. URL
Cristina Stasi, Silvia Fallani, Fabio Voller, Caterina Silvestri. Treatment for COVID-19: An overview. -2020. European Journal of Pharmacology. Vol.889. -P. 173644.
Yousuke Furuta, Takashi KOMENO, and Takaaki NAKAMURA Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase Proc. Jpn. Acad., Ser. -2017.-Vol.93.- Р. 449-463
Długosz-Pokorska, A., Pięta, M., Kędzia, J. et al. new uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line. -2020. BMC Pharmacol Toxicol Vol.21, -P. 18 Crossref.